Single Intranasal Mebufotenin Dose Cuts Depression Scores in Treatment-Resistant Depression
This phase 2b trial supplies the first controlled dose-comparison data for a short-acting intranasal psychedelic, with implications for monitoring burden and future dispensing models.
📅 Journal publication: Oct 26, 2026·Last updated: Nov 2, 2026
Intranasal mebufotenin offers fast relief for treatment-resistant depression.
Treatment-resistant depression poses a significant clinical challenge, and intranasal psychedelics may offer new treatment options with less intensive monitoring requirements. Intranasal mebufotenin benzoate significantly reduced Montgomery-Asberg Depression Rating Scale scores at both 8 mg and 12 mg doses compared to 0.3 mg, with rapid discharge readiness. This phase 2b study shows promise for intranasal mebufotenin as a well-tolerated option for treatment-resistant depression, although further validation in larger trials is needed. Intranasal mebufotenin offers rapid and durable symptom relief in treatment-resistant depression with shorter monitoring times.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Feifel D, Seynaeve M, Cubala WJ, Dunbar F, Gründer G, Dueñas Herrero RM, Hindocha C, Liknaitzky P, McGuigan SM, Mehta S, Pierce M, Repantis D, Roberts C, Wiegand F, Conley R
Citation:Feifel D, Seynaeve M, Cubala WJ, et al. Single Intranasal Administration of the Psychedelic Mebufotenin for Treatment-Resistant Depression: A Randomized Clinical Trial. JAMA. 2026. doi:10.1001/jama.2026.18380